{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:36Z","timestamp":1792782996408,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030018"],"award-info":[{"award-number":["82030018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971041"],"award-info":[{"award-number":["31971041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Foundation of Jiangxi Province","award":["20203AEI91005"],"award-info":[{"award-number":["20203AEI91005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10557-023-07425-4","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T03:03:11Z","timestamp":1673319791000},"page":"517-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients"],"prefix":"10.1007","volume":"38","author":[{"given":"Weiguo","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-0862","authenticated-orcid":false,"given":"Kui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"6","key":"7425_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/ijms20061324","volume":"20","author":"RM Lester","year":"2019","unstructured":"Lester RM, Paglialunga S, Johnson IA. QT assessment in early drug development: the long and the short of it. Int J Mol Sci. 2019;20(6):1324.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"7425_CR2","doi-asserted-by":"publisher","first-page":"e0199028","DOI":"10.1371\/journal.pone.0199028","volume":"13","author":"FM Fernandes","year":"2018","unstructured":"Fernandes FM, Silva EP, Martins RR, Oliveira AG. QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One. 2018;13(6):e0199028.","journal-title":"PLoS ONE"},{"issue":"6","key":"7425_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/11598160-000000000-00000","volume":"35","author":"JE Tisdale","year":"2012","unstructured":"Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012;35(6):459\u201370.","journal-title":"Drug Saf"},{"issue":"3","key":"7425_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcrc.2012.10.014","volume":"28","author":"MJ Armahizer","year":"2013","unstructured":"Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243\u20139.","journal-title":"J Crit Care"},{"issue":"5","key":"7425_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcrc.2014.05.005","volume":"29","author":"E Hoogstraaten","year":"2014","unstructured":"Hoogstraaten E, Rijkenberg S, van der Voort PH. Corrected QT-interval prolongation and variability in intensive care patients. J Crit Care. 2014;29(5):835\u20139.","journal-title":"J Crit Care"},{"issue":"2","key":"7425_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jsps.2018.11.003","volume":"27","author":"FM Fernandes","year":"2019","unstructured":"Fernandes FM, da Silva Paulino AM, Sedda BC, et al. Assessment of the risk of QT-interval prolongation associated with potential drug-drug interactions in patients admitted to Intensive Care Units. Saudi Pharm J. 2019;27(2):229\u201334.","journal-title":"Saudi Pharm J"},{"key":"7425_CR7","unstructured":"QT Drugs Lists. 2022. https:\/\/crediblemeds.org\/druglist. Accessed 26 May 2022."},{"issue":"1","key":"7425_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut and liver. 2017;11(1):27\u201337.","journal-title":"Gut and liver"},{"issue":"2","key":"7425_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.mayocp.2017.10.022","volume":"93","author":"AK Nehra","year":"2018","unstructured":"Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton pump inhibitors: review of emerging concerns. Mayo Clinic Proc. 2018;93(2):240\u20136.","journal-title":"Mayo Clinic Proc"},{"issue":"3","key":"7425_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrgastro.2011.272","volume":"9","author":"P Moayyedi","year":"2012","unstructured":"Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9(3):132\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"7425_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/17512433.2018.1531703","volume":"11","author":"V Savarino","year":"2018","unstructured":"Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123\u201334.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"7425_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.2012.462","volume":"83","author":"MA Perazella","year":"2013","unstructured":"Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553\u20136.","journal-title":"Kidney Int"},{"key":"7425_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2018.00363","volume":"9","author":"PE Lazzerini","year":"2018","unstructured":"Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front Pharmacol. 2018;9:363.","journal-title":"Front Pharmacol"},{"issue":"5","key":"7425_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2036.2012.05201.x","volume":"36","author":"MW Hess","year":"2012","unstructured":"Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"7425_CR15","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1161\/CIRCEP.112.000101","volume":"6","author":"JN Bibawy","year":"2013","unstructured":"Bibawy JN, Parikh V, Wahba J, et al. Pantoprazole (proton pump inhibitor) contributing to torsades de Pointes storm. Circ Arrhythm Electrophysiol. 2013;6(2):e17\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"7","key":"7425_CR16","doi-asserted-by":"publisher","first-page":"e010042","DOI":"10.1161\/CIRCEP.121.010042","volume":"14","author":"PE Lazzerini","year":"2021","unstructured":"Lazzerini PE, Cartocci A, Qu YS, et al. Proton pump inhibitors directly block hERG-potassium channel and independently increase the risk of QTc prolongation in a large cohort of US veterans. Circ Arrhythm Electrophysiol. 2021;14(7):e010042.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"7425_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/MCG.0000000000001420","volume":"55","author":"MR Rooney","year":"2021","unstructured":"Rooney MR, Bell EJ, Alonso A, et al. Proton pump inhibitor use, hypomagnesemia and risk of cardiovascular diseases: the atherosclerosis risk in communities (ARIC) study. J Clin Gastroenterol. 2021;55(8):677\u201383.","journal-title":"J Clin Gastroenterol"},{"key":"7425_CR18","doi-asserted-by":"publisher","unstructured":"Toews I, George AT, Peter JV, et al. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. Cochrane Database Syst Rev. 2018;6(6):CD008687. https:\/\/doi.org\/10.1002\/14651858.CD008687.pub2","DOI":"10.1002\/14651858.CD008687.pub2"},{"key":"7425_CR19","doi-asserted-by":"publisher","first-page":"160035","DOI":"10.1038\/sdata.2016.35","volume":"3","author":"AE Johnson","year":"2016","unstructured":"Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.","journal-title":"Sci Data"},{"issue":"9","key":"7425_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"6","key":"7425_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/0972-5229.158271","volume":"19","author":"TK George","year":"2015","unstructured":"George TK, Chase D, Peter JV, et al. Association between a prolonged corrected QT interval and outcomes in patients in a medical Intensive Care Unit. Indian J Crit Care Med. 2015;19(6):326\u201332.","journal-title":"Indian J Crit Care Med"},{"issue":"8","key":"7425_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047\u201360.","journal-title":"Circulation"},{"issue":"10","key":"7425_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013\u201322.","journal-title":"N Engl J Med"},{"issue":"13","key":"7425_CR24","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","volume":"67","author":"PJ Schwartz","year":"2016","unstructured":"Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67(13):1639\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"7425_CR25","first-page":"515","volume":"6","author":"E El-Charabaty","year":"2013","unstructured":"El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6:515\u20138.","journal-title":"Int J Gen Med"},{"issue":"16","key":"7425_CR26","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.jacc.2016.07.761","volume":"68","author":"T Lorberbaum","year":"2016","unstructured":"Lorberbaum T, Sampson KJ, Chang JB, et al. Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation. J Am Coll Cardiol. 2016;68(16):1756\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"7425_CR27","first-page":"1","volume":"2","author":"O Tasci","year":"2022","unstructured":"Tasci O, Kiran TE. Does the use of proton pump inhibitors in children affect ventricular repolarisation parameters? Cardiol Young. 2022;2:1\u20135.","journal-title":"Cardiol Young"},{"issue":"6","key":"7425_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12012-020-09577-3","volume":"20","author":"J Wolfes","year":"2020","unstructured":"Wolfes J, Ellermann C, Burde S, et al. Concomitant treatment with proton pump inhibitors and cephalosporins does not enhance QT-associated proarrhythmia in isolated rabbit hearts. Cardiovasc Toxicol. 2020;20(6):531\u20138.","journal-title":"Cardiovasc Toxicol"},{"key":"7425_CR29","doi-asserted-by":"crossref","unstructured":"Malihi G, Nikoui V, Elson EL. A review on qualifications and cost effectiveness of induced pluripotent stem cells (IPSCs)-induced cardiomyocytes in drug screening tests.\u00a0Arch Physiol Biochem. 2020;1\u201312.","DOI":"10.1080\/13813455.2020.1802600"},{"issue":"1","key":"7425_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1124\/mol.59.1.122","volume":"59","author":"J Kang","year":"2001","unstructured":"Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122\u20136.","journal-title":"Mol Pharmacol"},{"issue":"8","key":"7425_CR31","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.hrthm.2005.04.029","volume":"2","author":"J Guo","year":"2005","unstructured":"Guo J, Zhan S, Lees-Miller JP, Teng G, Duff HJ. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm. 2005;2(8):860\u20136.","journal-title":"Heart Rhythm"},{"issue":"2","key":"7425_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/sj.bjp.0702800","volume":"128","author":"AG Teschemacher","year":"1999","unstructured":"Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999;128(2):479\u201385.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"7425_CR33","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","volume":"158","author":"AH Glassman","year":"2001","unstructured":"Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774\u201382.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"7425_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12012-010-9074-y","volume":"10","author":"BJ Z\u00fcnkler","year":"2010","unstructured":"Z\u00fcnkler BJ, Wos-Maganga M. Comparison of the effects of methadone and heroin on human ether-\u00e0-go-go-related gene channels. Cardiovasc Toxicol. 2010;10(3):161\u20135.","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"7425_CR35","first-page":"614","volume":"295","author":"YA Kuryshev","year":"2000","unstructured":"Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000;295(2):614\u201320.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"7425_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000083234","volume":"74","author":"S Claassen","year":"2005","unstructured":"Claassen S, Z\u00fcnkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005;74(1):31\u20136.","journal-title":"Pharmacology"},{"issue":"3","key":"7425_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00228-011-1119-z","volume":"68","author":"H Asajima","year":"2012","unstructured":"Asajima H, Saito N, Ohmura Y, Ohmura K. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide. Eur J Clin Pharmacol. 2012;68(3):331\u20133.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"7425_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/pds.5428","volume":"31","author":"MM Assimon","year":"2022","unstructured":"Assimon MM, Pun PH, Al-Khatib SM, et al. Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. Pharmacoepidemiol Drug Saf. 2022;31(6):670\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7425_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jfma.2018.01.016","volume":"118","author":"Q Khan","year":"2019","unstructured":"Khan Q, Ismail M, Haider I, Ali Z. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. J Formos Med Assoc. 2019;118:109\u201315.","journal-title":"J Formos Med Assoc"},{"key":"7425_CR40","doi-asserted-by":"publisher","first-page":"l6722","DOI":"10.1136\/bmj.l6722","volume":"368","author":"Z Ye","year":"2020","unstructured":"Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020;368:l6722.","journal-title":"BMJ"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07425-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07425-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07425-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T02:24:00Z","timestamp":1715912640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07425-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["7425"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07425-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2167911\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"31 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethic approval for this study was no required since all data was obtained from a public database; MIMIC-III project was approved by Institutional Review Boards of Beth Israel Deaconess Medical Center (Boston, MA) and the Massachusetts Institute of Technology (Cambridge, MA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}